Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes.
Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes.
复制标题
DOI：
10.1136/openhrt-2015-000327
复制
发表时间：
2015
期刊：
影响因子：
2.7
通讯作者：
O'Keefe JH
中科院分区：
文献类型：
--
作者：
DiNicolantonio JJ;Bhutani J;O'Keefe JH
α-葡萄糖苷酶抑制剂（AGIs）是一类专门用于治疗或预防2型糖尿病的口服降糖药物。AGIs通过抑制碳水化合物转化为单糖（单糖）来改变肠道对碳水化合物的吸收，从而降低体内碳水化合物的生物利用度，显著降低血糖水平。临床使用的三种AGIs是阿卡波糖、伏格糖和米格列醇。本文将对阿卡波糖的心血管特性进行综述。目前可用的数据表明，AGIs（特别是阿卡波糖）对于治疗前驱糖尿病和糖尿病可能是安全有效的。
α-Glucosidase inhibitors (AGIs) are a class of oral glucose-lowering drugs used exclusively for treatment or prevention of type 2 diabetes mellitus. AGIs act by altering the intestinal absorption of carbohydrates through inhibition of their conversion into simple sugars (monosaccharides) and thus decrease the bioavailability of carbohydrates in the body, significantly lowering blood glucose levels. The three AGIs used in clinical practice are acarbose, voglibose and miglitol. This review will focus on the cardiovascular properties of acarbose. The current available data suggest that AGIs (particularly acarbose) may be safe and effective for the treatment of prediabetes and diabetes.